UnknownPhase 1/2

Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma

Israel25 participantsStarted 2006-11

Plain-language summary

Basal like breast carcinoma is a Her2, estrogen receptor (ER) progesterone receptor (PR) negative breast cancer. It is notable for the high level of epidermal growth factor receptor (EGFR) expression in this tumor subtype . Thus the investigators wanted to combine the use of anti EGFR therapy in the form of Erbitux (cetuximab) with the widely used weekly taxol chemotherapy for the treatment of these women. This is a small phase I/II study.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with metastatic breast carcinoma of the basal like subtype with available biopsy for analysis and ECOG PS of 2 or less Exclusion Criteria: * Pregnancy * BUN, blood creatinine, AST, ALT \> X3 of upper limits of normal * More than previous 2 chemotherapy lines in the metastatic settings or the use of previous inhibitors of EGFR

What they're measuring

tumor markers tumor size by ct

Timeframe: two years

Trial details

NCT IDNCT00353717

SponsorHadassah Medical Organization

Sponsor typeOTHER

Study typeINTERVENTIONAL

Contact for this trial

Hovav Nechushtan, MD/PhD

972-0508946057 hovavnech@hadassah.org.il

View on ClinicalTrials.gov More Breast Neoplasms trials